Employees of the Research Institute of Medicinal and Aromatic Plants (FGBNU VILAR) have improved the technology for obtaining the medicinal substance flacoside from Amur velvet leaves for the treatment of hepatitis A, B and C viruses, acute and recurrent herpes simplex of various localization, chicken pox and measles. This was reported to Gazeta.Ru at the Ministry of Science and Higher Education of the Russian Federation .
Amur velvet grows wild in the Far East in the Amur Region , as well as in the Primorsky and Khabarovsk Territories. According to scientists, now the plant is successfully grown in other regions of Russia , for example, in the Bryansk region .
The presence of a sufficient raw material base, a rational technology for obtaining the substance and its high efficiency will make it possible to produce a medicinal herbal preparation from Amur velvet leaves and successfully use it for the prevention and treatment of a wide range of viral infections.
“The results of clinical studies have shown that the drug from Amur velvet has an antiviral effect against hepatitis A and B, acute and recurrent herpes simplex of various localization, chicken pox and measles, and also has hepatoprotective properties. Along with this, the experiment established the activity of this substance against the hepatitis C virus. The created technology makes it possible to obtain a high-quality product with the rational use of raw materials and excipients,” a leading researcher at the Department of Chemistry of Natural Compounds and one of the main authors told Gazeta.Ru of this development VILAR Olga Sheichenko.
The drug “Flakozid” is an antiviral drug of plant origin. In 1979, scientists received a patent under the heading “for official use”, and in the 1990s the drug was produced for a short time.
Now work on the drug has resumed due to a shortage of domestic antiviral drugs on the market. The new production technology makes it possible to obtain a medicinal substance with a high yield and with a minimum amount of impurities.
At present, the employees of the institute have completed research on improving the technology for obtaining the substance and, together with CJSC VIFITECH, have received experimental batches. The substance “Flakozid” is registered in the State Register of Medicines. The next step is the registration of the dosage form (tablet).
